Welcome to our Evotec Blog.

Hope you will find our articles and resources relevant for your projects and interests.

Our experts are available for any additional information and to assist with your project challenges!

Just contact us.

 

 

2018

Evotec and LEO Pharma form drug discovery alliance targeting dermatological conditions
Nerina Coppini, 4 December 2018

Identify new leads for innovative targets in the dermatology field The alliance will use Evotec's world leading drug discovery platform

Ferring and Evotec form strategic research alliance in reproductive medicine and women’s health
Nerina Coppini, 17 October 2018

Ferring accesses Evotec's integrated small molecule discovery and development platform to progress new molecules from concept to potential drug candidates Evotec is eligible for undisclosed research funding and milestones 

Evotec and Novo Nordisk form strategic research alliance in diabetes and obesity
Nerina Coppini, 22 August 2018

The alliance builds upon Evotec's leading drug discovery and development capabilities in diabetes and related co-morbidities Novo Nordisk accesses Evotec's integrated discovery and development platform to progress new molecules from concept to IND including Evotec's INDiGO platform

2017

Evotec AG announces first nine-month 2017 results and corporate update
Laura Catalina, 8 November 2017

Strong operational and financial performance Expansion of leading external innovation platform through acquisition of aptuit Important milestone achievements and new ways of accelerating innovation Hamburg, Germany, 08 November 2017: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) today reported financial results and...

Evotec joins forces with Academic Leaders to accelerate Drug Discovery in kidney diseases and build “Neplex”
Laura Catalina, 7 November 2017

Collaboration aimed at developing novel “Nephron-on-a Chip” device to test drug candidates in human kidney: NEPLEX (“Nephron-on-a-Chip with Cellular and Extracellular Matrix Complexity”) Major step forward to the next generation Kidney Platform Hamburg, Germany, 06 November 2017:Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN:...

New Research by Cyprotex on Transporter DDI Published in Pharmacology Research & Perspectives
Laura Catalina, 31 October 2017

New research by Cyprotex in the field of metformin drug-drug interactions has been published in Pharmacology Research & Perspectives. The publication assists in further understanding the mechanism behind clinically observed DDIs with the common co-medication, metformin. Read our blog and download the publication. Cyprotex offers a full range of ...

Evotec and Tesaro Enter Strategic Partnership To Discover Novel Immuno-Oncology Agents
Laura Catalina, 26 October 2017

Discovery and development of inhibitors against Tesaro's Immuno-Oncology target utilising Evotec's comprehensive discovery and development platform Hamburg, Germany, 26 October 2017: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) and TESARO, Inc. (“TESARO”) today announced a three-year integrated drug discovery...

Evotec Achieves First Milestone In Neurodegeneration Alliance With Celgene
Laura Catalina, 10 October 2017

Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) announced today that its strategic alliance with Celgene has reached a first milestone triggering revenues of $ 5.0 m to Evotec, which are recognised in the third quarter of 2017. The milestone is due to the successful completion of a screening campaign using Evotec’s induced...

Evotec and MaRS Innovation Establish Academic Bridge “LAB150” in Toronto
Nerina Coppini, 14 September 2017

We are pleased to share the press release about the launch of “LAB150” announced by Evotec and MaRS Innovation.

Evotec to Acquire Aptuit, Expanding Leadership in External Innovation
Nerina Coppini, 30 July 2017

We are pleased to share the press release published today about the agreement between Evotec AG and Aptuit under which Evotec will acquire Aptuit.

 

 

Contact us

Evotec

Business Development

T +44.(0)1235.86 15 61 T +1.732 329 2355 x3308